## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -2.8% below STRENGTH zone (4.0-10.0%); PEG 3.10 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Colgate-Palmolive Company $CL Shares Sold by Panagora Asset Management Inc.**
- Source: MarketBeat | 20251203T123157 | Neutral | Relevance: 100%
- Panagora Asset Management Inc. significantly reduced its stake in Colgate-Palmolive (CL) by 78.8% in Q2, selling nearly a million shares. Despite this, the stock maintains a "Moderate Buy" consensus rating from analysts with an average target price of $89.87. The company recently reported strong quarterly earnings, beating EPS estimates, and announced a quarterly dividend.

**2. Loomis Sayles & Co. L P Acquires 15,197 Shares of Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251203T115058 | Somewhat-Bullish | Relevance: 100%
- Loomis Sayles & Co. L P increased its stake in Colgate-Palmolive Company by 17.8%, acquiring an additional 15,197 shares to reach a total of 100,374 shares valued at $9.12 million. Other major institutions like Vanguard, Price T. Rowe, and Norges Bank also significantly increased their holdings, bringing institutional ownership to approximately 80.41%. While analysts have recently lowered price targets, the consensus remains a "Moderate Buy" with a target price of $89.87, and the company offers a quarterly dividend of $0.52.

**3. Arrowstreet Capital Limited Partnership Decreases Stock Holdings in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251202T082138 | Neutral | Relevance: 100%
- Arrowstreet Capital Limited Partnership reduced its stake in Colgate-Palmolive Company by 3.6% in Q2 2025, selling 247,532 shares, though still holding 6,544,108 shares worth approximately $594.9 million. Meanwhile, OMERS ADMINISTRATION Corp significantly increased its position by 2,890.5%. The stock trades near $80, offers a 2.6% dividend yield, and has a "Moderate Buy" consensus rating from analysts despite recent price target cuts.

**4. Scotia Capital Inc. Raises Stock Holdings in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251201T150602 | Neutral | Relevance: 100%
- Scotia Capital Inc. increased its stake in Colgate-Palmolive Company by 7.8% in Q2 2025, reaching 68,962 shares valued at $6.27 million. This move comes as Colgate-Palmolive reported Q3 EPS slightly above consensus and maintains a dividend yield of approximately 2.6%. The company is largely held by institutional investors and has a consensus "Moderate Buy" rating from analysts, despite recent target adjustments.

**5. Railway Pension Investments Ltd Cuts Stake in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251201T125110 | Neutral | Relevance: 100%
- Railway Pension Investments Ltd reduced its stake in Colgate-Palmolive Company by 8.3% during the 2nd quarter, selling 71,800 shares. Despite this reduction, other institutional investors like Norges Bank, Price T Rowe Associates Inc. MD, and Schroder Investment Management Group significantly increased their holdings in Colgate-Palmolive. The article also details Colgate-Palmolive's stock performance, recent earnings, dividend announcement, and current analyst ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 7)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-04 | Barclays | $80 | $82 | -2% |
| 2025-11-03 | UBS | $90 | $92 | -2% |
| 2025-11-03 | Citigroup | $95 | $105 | -10% |
| 2025-11-03 | Morgan Stanley | $87 | $96 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-04 | Barclays | main | Equal-Weight |
| 2025-11-03 | UBS | main | Buy |
| 2025-11-03 | Citigroup | main | Buy |
| 2025-11-03 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Valuation stretched: PEG 3.1x requires aggressive growth execution.
2. Long-term trend broken: trading 9.6% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.10 signals overvaluation risk, limited margin of safety. Forward P/E 20.4x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Analyst sentiment negative (7 target cuts vs 0 raises). Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $64.4B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.10 |
| Forward P/E | 20.4 |
| Current P/E | 21.4 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.5% to -2.8% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 46. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.82% (CS: 24) | Weak |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | -0.00 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 0.904x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.20
- **Stop Loss:** $75.38 (3.6% risk)
- **Target:** $81.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 336
- **Position Value:** $26,275.20
- **Portfolio %:** 26.28%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*